Intellia Therapeutics stock
NTLANASDAQIntellia Therapeutics, Inc., HealthcareISIN US45826J1051
34Score 34 out of 100, Weak
Price and trend
40 / 100
Price history
+11% in one yearThe chart shows daily closes over 11 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 19% below it.
Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 46).
The price is 41% below its 52-week high. Largest decline in 11 years: 96% (September 2021 to April 2025).
Chart figures for advanced users
- SMA 50$11.98
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$12.98
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)46
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$8.04
- The lowest closing price of the last twelve months.
- Resistance$17.84
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Intellia Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.48B, is number 151 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $67.67M (up 16.9% year on year) and a loss of $412.69M.
- For fiscal 2026, analysts expect on average revenue of $50.26M (down 25.7%) and adjusted earnings per share of −$3.20.
Show more
- MEQIRI Score 34 out of 100 (Weak): rank 652 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $474.11M, financial debt $230.14M.Stability 65
Weaknesses
- DilutionShare count up 94% since 2020.Capital allocation 18
- Loss-makingLoss of $426.14M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$358.08M over the last 12 months.Fundamentals 17
The score is held back by capital allocation and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 8.1% on the twelve months before. Revenue turned from negative at the start of the period to positive ($67.67M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 76%, operating −652%, net −610%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is moderate; no interest coverage is reported.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported −$0.91 (expected −$0.80)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$3.20+0.1%
- Revenue
- $50.26M0.0%
- Earnings per share
- −$2.63+0.1%
- Revenue
- $121.15M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +8.8%No change: FDA acceptance of the BLA filing is expected by year end, with a U.S. launch expected in the first half of 2027.
“Importantly, while we expect to obtain approval and launch lonvo-z in the U.S, in the first half of 2027, our cash runway guidance is conservative in that it excludes all product revenues.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $637,649 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Leonard John MSale
2 Nov 2026, President and CEO
- Shares
- 9,000
- Price
- $11.99
- Value
- $107,910
- Dube Michael PSale
2 Oct 2026, VP, Chief Accounting Officer
- Shares
- 1,864
- Price
- $12.43
- Value
- $23,170
- Leonard John MSale
21 Aug 2026, President and CEO
- Shares
- 2,785
- Price
- $13.00
- Value
- $36,205
Show 4 more
- Leonard John MSale
20 Aug 2026, President and CEO
- Shares
- 19,890
- Price
- $12.60
- Value
- $250,614
- Dulac Edward J IIISale
22 Jul 2026, EVP, Chief Financial Officer
- Shares
- 8,111
- Price
- $11.25
- Value
- $91,249
- Dulac Edward J IIISale
2 Jul 2026, EVP, Chief Financial Officer
- Shares
- 4,677
- Price
- $18.00
- Value
- $84,186
- Dube Michael PSale
1 Jul 2026, VP, Chief Accounting Officer
- Shares
- 2,641
- Price
- $16.78
- Value
- $44,316
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Intellia Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 34
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- SELLAS Life Sciences GroupSLS $1.7B36
- PrecigenPGEN $1.69B55
- NanobiotixNANO.PA $1.65B38
- NovavaxNVAX $1.65B45
- Immunocore HoldingsIMCR $1.6B47
- Taysha Gene TherapiesTSHA $1.58B36
- Nuvation BioNUVB $1.51B31
- Ocular TherapeutixOCUL $1.46B35
ETFs that hold Intellia Therapeutics
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 0.99% | 0.50% | €127.06M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.10% | 0.35% | €1.21B |
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.07% | 0.30% | €185.82M |
Show 5 more
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.06% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.05% | 0.30% | €4.22B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2017)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.